Get started
SATELLOS BIOSCIENCE INCSS

SATELLOS BIOSCIENCE INC

0.89CADD
+0.02+2.30%
At close at 19:55 GMT
CAD
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

MSCL fundamentals

Key facts

Market capitalization‪133.44 M‬CAD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.25CAD
Founded2012
Employees (FY)12
CEOFrank Gleeson
Websitesatellos.com
About

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

Ownership
‪‪153.38 M‬‬
Free Float shares
‪‪127.87 M‬‬ (83.37%)
Closely held shares
‪‪25.50 M‬‬ (16.63%)
Free Float shares
‪‪127.87 M‬‬ (83.37%)
Closely held shares
‪‪25.50 M‬‬ (16.63%)
Capital structure
Market cap
‪‪133.44 M‬‬
Cash & equivalents
‪‪23.42 M‬‬
Enterprise value
‪‪110.01 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪133.44 M‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24

Growth and Profitability

Company’s recent performance and margins

Performance
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−10.00 M‬‬
‪‪−7.50 M‬‬
‪‪−5.00 M‬‬
‪‪−2.50 M‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−10.00 M‬‬
‪‪−7.50 M‬‬
‪‪−5.00 M‬‬
‪‪−2.50 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−10.00 M‬‬
‪‪−7.50 M‬‬
‪‪−5.00 M‬‬
‪‪−2.50 M‬‬
‪0.00‬

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
Actual
Estimate
Earnings
Next:Mar 27, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−0.08‬
‪−0.06‬
‪−0.04‬
‪−0.02‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

MSCL does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−8.00 M‬‬
‪0.00‬
‪‪8.00 M‬‬
‪‪16.00 M‬‬
‪‪24.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪7.00 M‬‬
‪‪14.00 M‬‬
‪‪21.00 M‬‬
‪‪28.00 M‬‬
Assets
Liabilities